LIFECORE BIOMEDICAL, INC. LIFECORE BIOMEDICAL INC - PROPOSED DEAL FOR $17.5 MLN IN CASH
Lifecore Biomedical Inc - Proposed Deal For $17.5 Mln In Cash…
February 07, 2023 at 04:30 pm EST
Share
Share
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.45 USD | +2.14% |
|
+7.10% | +4.85% |
| Apr. 01 | Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024 | CI |
| Mar. 27 | Lifecore Biomedical Searches for New Auditor for Fiscal Year 2024 | MT |
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
Sector
Pharmaceuticals
Calendar
2024-07-29
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
6.315
USD
Average target price
6
USD
Spread / Average Target
-4.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.85% | 193M | |
| +24.88% | 672B | |
| +24.08% | 550B | |
| -6.34% | 351B | |
| +15.10% | 317B | |
| +7.38% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -10.37% | 144B | |
| -7.19% | 141B |
- Stock Market
- Equities
- LFCR Stock
- News Lifecore Biomedical, Inc.
- Lifecore Biomedical Inc - Proposed Deal For $17.5 Mln In Cash…
